# GlaxoSmithKline Pharmaceuticals (NSE: GLAXO) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/GLAXO · Pivot · prices to 22 Oct 2026

GlaxoSmithKline Pharmaceuticals (NSE: GLAXO) closed at ₹2,455.20 on 22 Oct 2026, up 0.17% on the day. With a market capitalisation of ₹41,228 Cr, it ranks 218th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - General.

At its last close the stock traded at 40.1× trailing earnings, against a return on equity of 47.7% in FY25. Over the past year the share price has fallen 9.1%. Its 52-week range is ₹2,088.10 (12 Jun 2026) to ₹3,120.70 (28 Aug 2026); the last close is 21.3% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹938 Cr (+16.6% year on year) and net profit ₹237 Cr (+15.7%), on a consolidated basis. Promoters held 75.00% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹2,455.20 |
| Market cap | ₹41,228 Cr |
| P/E (trailing) | 40.1 |
| ROE | 47.7% (FY25) |
| ROCE | 57.0% (FY25) |
| Debt to equity | 0 |
| 52-week high | ₹3,120.70 (28 Aug 2026) |
| 52-week low | ₹2,088.10 (12 Jun 2026) |
| 1-year return | −9.1% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹938 Cr | +16.6% | ₹237 Cr | +15.7% | ₹14.00 |
| Q4 FY26 | ₹995 Cr | +2.1% | ₹278 Cr | +5.7% | ₹16.40 |
| Q3 FY26 | ₹1,041 Cr | +9.7% | ₹296 Cr | +28.6% | ₹16.54 |
| Q2 FY26 | ₹980 Cr | −3.1% | ₹257 Cr | +2.0% | ₹15.20 |
| Q1 FY26 | ₹805 Cr | −1.2% | ₹205 Cr | +12.4% | ₹12.10 |
| Q4 FY25 | ₹974 Cr | +4.8% | ₹263 Cr | +35.2% | ₹15.52 |
| Q3 FY25 | ₹949 Cr | +17.9% | ₹230 Cr | +402.8% | ₹13.57 |
| Q2 FY25 | ₹1,011 Cr | +5.6% | ₹253 Cr | +16.1% | ₹14.91 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹3,749 Cr | ₹928 Cr |
| FY24 | ₹3,454 Cr | ₹590 Cr |
| FY23 | ₹3,252 Cr | ₹611 Cr |
| FY22 | ₹3,278 Cr | ₹1,695 Cr |
| FY21 | ₹2,926 Cr | ₹358 Cr |
| FY20 | ₹3,224 Cr | ₹93 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 75.00%
- Foreign institutions: 4.79%
- Domestic institutions: 7.80%
- Non-institutions: 12.41%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [IPCA Laboratories](https://app.pivotnow.in/stock/IPCALAB) | ₹1,932.90 | ₹48,293 Cr | 43 | 14.2% |
| [Gland Pharma](https://app.pivotnow.in/stock/GLAND) | ₹2,910.60 | ₹47,020 Cr | 46.7 | 9.9% |
| [Anthem Biosciences](https://app.pivotnow.in/stock/ANTHEM) | ₹802.40 | ₹45,113 Cr | 76.6 | 19.4% |
| [Ajanta Pharma](https://app.pivotnow.in/stock/AJANTPHARM) | ₹3,260.00 | ₹40,861 Cr | 38.6 | 23.3% |
| [Narayana Hrudayalaya](https://app.pivotnow.in/stock/NH) | ₹1,691.90 | ₹34,602 Cr | 42.4 | 17.8% |
| [Emcure Pharmaceuticals](https://app.pivotnow.in/stock/EMCURE) | ₹1,759.20 | ₹33,812 Cr | 145.1 | 18.7% |

## Questions and answers

### What is the share price of GlaxoSmithKline Pharmaceuticals today?

GlaxoSmithKline Pharmaceuticals (NSE: GLAXO) last closed at ₹2,455.20 on 22 Oct 2026. Its 52-week high is ₹3,120.70 and its 52-week low is ₹2,088.10.

### What is the market cap of GlaxoSmithKline Pharmaceuticals?

GlaxoSmithKline Pharmaceuticals' market capitalisation is ₹41,228 Cr (₹41,228 Cr) at the 22 Oct 2026 close, ranking 218th among the NSE companies Pivot tracks.

### What is the P/E ratio of GlaxoSmithKline Pharmaceuticals?

GlaxoSmithKline Pharmaceuticals trades at a trailing P/E of 40.1. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 46.7.

### What is the ROE and ROCE of GlaxoSmithKline Pharmaceuticals?

Return on equity was 47.7% in FY25 and return on capital employed was 57.0% in FY25 (consolidated figures).

### Is GlaxoSmithKline Pharmaceuticals a debt-free company?

GlaxoSmithKline Pharmaceuticals is close to debt-free: its debt-to-equity ratio was 0 in FY25.

### What were GlaxoSmithKline Pharmaceuticals' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), GlaxoSmithKline Pharmaceuticals reported revenue of ₹938 Cr, +16.6% year on year, and net profit of ₹237 Cr, +15.7% year on year.

### How has GlaxoSmithKline Pharmaceuticals stock performed over the last year?

GlaxoSmithKline Pharmaceuticals' share price has fallen 9.1% over the past year, −3.9% over three months and −14.5% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of GlaxoSmithKline Pharmaceuticals?

As of 30 Jun 2026: promoters 75.00%, foreign institutions 4.79%, domestic institutions 7.80%, non-institutions 12.41%.

### Who are GlaxoSmithKline Pharmaceuticals' competitors?

The listed Pharma & Healthcare companies closest to GlaxoSmithKline Pharmaceuticals by market cap are IPCA Laboratories, Gland Pharma, Anthem Biosciences, Ajanta Pharma, Narayana Hrudayalaya and Emcure Pharmaceuticals.

### Is GlaxoSmithKline Pharmaceuticals a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out GlaxoSmithKline Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on GLAXO against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.